Novartis is developing LAF-237, one of a series of orally active dipeptidylpeptidase IV inhibitors, as a potential once daily therapeutic agent for type 2 diabetes. Phase III trials began in the first quarter of 2004.
LAF-237 (Novartis) [Recensione] / D. Barlocco. - In: CURRENT OPINION IN INVESTIGATIONAL DRUGS. - ISSN 1472-4472. - 5:10(2004), pp. 1094-1100.
LAF-237 (Novartis)
D. BarloccoPrimo
2004
Abstract
Novartis is developing LAF-237, one of a series of orally active dipeptidylpeptidase IV inhibitors, as a potential once daily therapeutic agent for type 2 diabetes. Phase III trials began in the first quarter of 2004.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
